Transmissible Spongiform Encephalopathies Advisory Committee; Amendment of Notice, 54500 [E6-15283]
Download as PDF
<![CDATA[
54500
Federal Register / Vol. 71, No. 179 / Friday, September 15, 2006 / Notices
grantee for the final budget and project
periods of Grant No. 90CVO172.
Big Brothers Big Sisters of Clinton and
Ionia Counties was responsible for
assisting children in Clinton and Ionia
Counties whose parents are incarcerated
to alleviate risk factors and to improve
their quality of life by providing them
with specially-trained adult mentors
who can provide supportive
relationships, guidance and
encouragement. As Big Brothers Big
Sisters of Michigan Capital Region is
proposing to continue services to the
same community with the same staff as
previously done by Big Brothers Big
Sisters of Clinton and Iona Counties, the
Family and Youth Services Bureau
(FYSB) is requesting that Big Brothers
Big Sisters of Michigan Capital Region
be granted a deviation to be funded as
the permanent successor grantee
without competition for the remaining
twelve months of the project period.
FOR FURTHER INFORMATION CONTACT:
Curtis Porter, Director, Youth
Development Division, Family and
Youth Services Bureau, Administration
for Children, Youth and Families,
Administration for Children and
Families, Portals Building, Suite 800,
1250 Maryland Avenue, SW.,
Washington, DC 20024. Telephone:
202–205–8102
Dated: September 8, 2006.
Joan E. Ohl,
Commissioner, Administration on Children,
Youth and Families.
[FR Doc. E6–15324 Filed 9–14–06; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Transmissible Spongiform
Encephalopathies Advisory
Committee; Amendment of Notice
AGENCY:
Food and Drug Administration,
HHS.
jlentini on PROD1PC65 with NOTICES
ACTION:
Notice.
The Food and Drug Administration
(FDA) is announcing an amendment to
the notice of the meeting of the
Transmissible Spongiform
Encephalopathies Advisory Committee.
This meeting was announced in the
Federal Register of August 3, 2006 (71
FR 44035). The amendment is being
made to reflect a change in the Date and
Time, Agenda, and Procedure portions
of the document. Specifically, the open
public hearing times in the Procedure
portion of the document were changed.
Because of a change in the agenda, the
VerDate Aug<31>2005
14:51 Sep 14, 2006
Jkt 208001
afternoon committee discussion topic
will be cancelled. There are no changes
other than those stated in this
announcement.
FOR FURTHER INFORMATION CONTACT:
William Freas or Rosanna L. Harvey,
Center for Biologics Evaluation and
Research (HFM–71), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852–1448, 301–827–
0314, or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512392.
SUPPLEMENTARY INFORMATION: In the
Federal Register of August 3, 2006, FDA
announced that a meeting of the
Transmissible Spongiform
Encephalopathies Advisory Committee
would be held September 18, 2006 from
8 a.m. to 4:30 p.m. and September 19,
2006 from 8 a.m. to 1 p.m. On page
44035, in the third column, the Date
and Time portion of the notice is
amended to read as follows:
Date and Time: The meeting will be
held on September 18, 2006, from 8:30
a.m. to 4 p.m. and September 19, 2006,
from 8 a.m. to 1 p.m.
On page 44036, in the first column,
the Agenda and Procedure portions of
the notice are amended to read as
follows:
Agenda: On September 18, 2006, the
committee will hear updates on the
following topics: United States and
worldwide bovine spongiform
encephalopathies (BSE); variant
Creutzfeldt-Jakob disease (vCJD)
epidemiology and transfusiontransmission; blood and plasma donor
deferral for transfusion in France since
1980 guidance; and critical factors
influencing prion decontamination
using sodium hydroxide. The committee
will then discuss experimental
clearance of transmissible spongiform
encephalopathy infectivity in plasmaderived Factor VIII products. In the
afternoon, the committee will hear
updates on the status of FDA’s initiative
on communication of the potential
exposure to vCJD risk from an
investigational product, plasma derived
FACTOR XI that was manufactured
from UK donor plasma, and a summary
of World Heath Organization
consultation on distribution of
infectivity in tissues of animals and
humans with transmissible spongiform
encephalopathies. On September 19,
2006, the committee will discuss
possible criteria for approval of donor
screening tests for vCJD.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
submissions may be made to the contact
person on or before September 6, 2006.
Oral presentations from the public will
be scheduled between approximately
11:30 a.m. and 12 noon and 3:30 p.m.
and 4 p.m. on September 18, 2006, and
between approximately 11:25 a.m. and
11:45 a.m. on September 19, 2006. Time
allotted for each presentation may be
limited. Those desiring to make formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before September 11, 2006.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app.2) and 21 CFR part 14,
relating to the advisory committees.
Dated: September 6, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and
Planning.
[FR Doc. E6–15283 Filed 9–14–06; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Health Resources
and Services Administration (HRSA)
publishes abstracts of information
collection requests under review by the
Office of Management and Budget
(OMB), in compliance with the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35). To request a copy of
the clearance requests submitted to
OMB for review, call the HRSA Reports
Clearance Office on (301) 443–1129.
The following request has been
submitted to the Office of Management
and Budget for review under the
Paperwork Reduction Act of 1995:
Proposed Project: Faculty Loan
Repayment Program (FLRP)
Application (OMB No. 0915–0150)—
Extension
Under the Health Resources and
Services Administration Faculty Loan
Repayment Program, health profession
graduates from a disadvantaged
background may enter into a contract
under which HRSA, with the
Department of Health and Human
Services, will make payments on
E:\FR\FM\15SEN1.SGM
15SEN1
]]>Agencies
[Federal Register Volume 71, Number 179 (Friday, September 15, 2006)]
[Notices]
[Page 54500]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-15283]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Transmissible Spongiform Encephalopathies Advisory Committee;
Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing an amendment
to the notice of the meeting of the Transmissible Spongiform
Encephalopathies Advisory Committee. This meeting was announced in the
Federal Register of August 3, 2006 (71 FR 44035). The amendment is
being made to reflect a change in the Date and Time, Agenda, and
Procedure portions of the document. Specifically, the open public
hearing times in the Procedure portion of the document were changed.
Because of a change in the agenda, the afternoon committee discussion
topic will be cancelled. There are no changes other than those stated
in this announcement.
FOR FURTHER INFORMATION CONTACT: William Freas or Rosanna L. Harvey,
Center for Biologics Evaluation and Research (HFM-71), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-
0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-
443-0572 in the Washington, DC area), code 3014512392.
SUPPLEMENTARY INFORMATION: In the Federal Register of August 3, 2006,
FDA announced that a meeting of the Transmissible Spongiform
Encephalopathies Advisory Committee would be held September 18, 2006
from 8 a.m. to 4:30 p.m. and September 19, 2006 from 8 a.m. to 1 p.m.
On page 44035, in the third column, the Date and Time portion of the
notice is amended to read as follows:
Date and Time: The meeting will be held on September 18, 2006, from
8:30 a.m. to 4 p.m. and September 19, 2006, from 8 a.m. to 1 p.m.
On page 44036, in the first column, the Agenda and Procedure
portions of the notice are amended to read as follows:
Agenda: On September 18, 2006, the committee will hear updates on
the following topics: United States and worldwide bovine spongiform
encephalopathies (BSE); variant Creutzfeldt-Jakob disease (vCJD)
epidemiology and transfusion-transmission; blood and plasma donor
deferral for transfusion in France since 1980 guidance; and critical
factors influencing prion decontamination using sodium hydroxide. The
committee will then discuss experimental clearance of transmissible
spongiform encephalopathy infectivity in plasma-derived Factor VIII
products. In the afternoon, the committee will hear updates on the
status of FDA's initiative on communication of the potential exposure
to vCJD risk from an investigational product, plasma derived FACTOR XI
that was manufactured from UK donor plasma, and a summary of World
Heath Organization consultation on distribution of infectivity in
tissues of animals and humans with transmissible spongiform
encephalopathies. On September 19, 2006, the committee will discuss
possible criteria for approval of donor screening tests for vCJD.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
September 6, 2006. Oral presentations from the public will be scheduled
between approximately 11:30 a.m. and 12 noon and 3:30 p.m. and 4 p.m.
on September 18, 2006, and between approximately 11:25 a.m. and 11:45
a.m. on September 19, 2006. Time allotted for each presentation may be
limited. Those desiring to make formal oral presentations should notify
the contact person and submit a brief statement of the general nature
of the evidence or arguments they wish to present, the names and
addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
September 11, 2006.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app.2) and 21 CFR part 14, relating to the advisory committees.
Dated: September 6, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E6-15283 Filed 9-14-06; 8:45 am]
BILLING CODE 4160-01-S
